Researchers at Columbia are looking at new treatments to help delay the start of menopause. This is a randomized trial where some women will receive medication and some will receive a placebo. The study will last approximately 12 weeks, followed by monthly follow-ups for 6 months. Participants will be compensated $1300 for compensation.
This study will test a computer-based behavioral intervention to decrease cocaine use. Those who fail to achieve cocaine abstinence after the first 4 weeks while receiving the behavioral treatment will continue the behavioral treatment and be randomly assigned to one of two groups (one group will receive Adderall-XR (MAS-ER) and the other group will receive…
The study is a two group outpatient study, one group receiving medications (Adderall-XR and topiramate) and one group receiving a placebo (inactive sugar pill). The study is looking at the safety and effectiveness of Adderall-XR (MAS-ER) and topiramate in the treatment of cocaine dependence. It is a 14-week trial that requires patients to attend visits 3…
The purpose of this study is to evaluate a new experimental (investigational) oral combination hormone drug product containing estradiol (a form of the estrogen) and progesterone (a female hormone that regulates the inner lining of the uterus called the endometrium) for postmenopausal women who have hot flushes. The estradiol and progesterone used in this…
The purpose of this study is to evaluate the efficacy and safety of ION-682884 given for 24 months in patients with hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN) also known as Familial Amyloid Polyneuropathy (FAP), and determine if it can help people with mild or moderate polyneuropathy. To be in this study you must have FAP and be…
HELIOS-A is a global Phase 3 randomized, open-label study designed to evaluate the safety and efficacy of ALN-TTRSC02 in adult patients with hATTR amyloidosis experiencing neurologic symptoms brought on by the disease. The study will also evaluate any changes in quality of life experienced by study participants. ALN-TTRSC02 utilizes the mechanism of RNA…